From market-moving scoops and exclusive interviews to investigative reports and insightful commentary — this is Reuters Best.
REUTERS EXCLUSIVELY REPORTED U.S. APPROVAL OF MERCK CANCER IMMUNOTHERAPY EXPECTED SOON
Reuters exclusively reported that U.S. regulators are likely to approve Merck & Co’s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline. If approved by the Food...Read More
REUTERS IFR AHEAD IN REPORTING SINOPEC PLANNING $1.5 BLN HONG KONG IPO FOR OILFIELD SERVICES UNIT
Reuters IFR was ahead in reporting that Asia’s largest refiner Sinopec is planning a $1.5 billion Hong Kong initial public offering for its oilfield services unit in the first half of 2015. Investment banks were recently invited to pitch for...Read More
by Financial Sector
Search on topics and regions relevant to your business.Go to archive